Skip to content Skip to footer
Subscribe Now
NEWS

Biocytogen Collaborates with Whitehawk Therapeutics to Develop Bispecific ADC

Shots: Biocytogen has entered into a global collaboration with Whitehawk Therapeutics to develop bispecific antibody-drug conjugates (BsADCs) Biocytogen will provide ~5 bispecific antibodies from its RenLite platform & Whitehawk will evaluate these in combination with its ADC linker-payload technologies, with Whitehawk holding the option to advance resulting BsADC candidates Biocytogen will receive an upfront payment,…
July 8, 2026

Read more

NEWS

Alcon Partners with RxSight to Develop Adjustable PCIOLs

Shots: Alcon has entered into a non-exclusive collaboration with RxSight to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) Under the collaboration, RxSight & Alcon will combine RxSight’s post-operative light-adjustable technology with Alcon’s PCIOL optical designs to co-develop adjustable PCIOLs for optimized cataract surgery outcomes As per the deal, RxSight will lead development & manufacturing, receiving…
July 7, 2026

Read more

NEWS

Astex Pharmaceuticals Partners with Genentech for Breast Cancer Therapy Program in a Deal Worth Over $490M

Shots: Astex has entered into an exclusive, worldwide research collaboration & license agreement with Genentech to identify small molecules with selective inhibitory activity for the treatment for breast cancer Astex will license compounds from its breast cancer discovery program to Genentech and jointly optimize lead compounds through preclinical candidate selection, after which Genentech will lead…
July 6, 2026

Read more

NEWS

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…
July 6, 2026

Read more

NEWS

CSPC Group and AstraZeneca Partner to Develop siRNA Drugs in ~$1.77B Deal

Shots: CSPC & AstraZeneca have entered into a strategic collaboration, option & license agreement to leverage CSPC’s siRNA discovery & extrahepatic targeted delivery platforms to develop novel small nucleic acid therapeutics CSPC & AstraZeneca will jointly discover & develop preclinical candidates for two renal disease targets, with AstraZeneca holding options for global/ex-China rights to each…
July 3, 2026

Read more

NEWS

Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery

Shots: Insilico Medicine has entered into a strategic collaboration agreement with Takeda to advance clinically differentiated drug candidates across Takeda's therapeutic areas, using Insilico’s Pharma.AI platform Insilico will lead AI-driven discovery, while Takeda will advance selected candidates through clinical development & hold exclusive worldwide rights to develop, manufacture, & commercialize resulting therapeutics As per the…
July 2, 2026

Read more

NEWS

Antares Therapeutics Inks ~$1.9B Deal with Novartis for Undruggable Oncology Targets

Shots: Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop & commercialize small molecule therapies against undruggable oncology targets Antares will lead research & apply its discovery engine to a select number of historically undruggable targets until option exercise, while continuing to advance its wholly owned & partnered precision medicine pipeline…
June 25, 2026

Read more

NEWS

Combotope Therapeutics and Boehringer Ingelheim Collaborate on Next-Generation Cancer Antibody Therapies

Shots: BI has entered into a strategic research collaboration with Combotope to leverage its SMART-Phage platform to produce highly tumor-selective antibodies for next-generation cancer therapies Combotope will discover tumor-selective, high-affinity antibodies against multiple BI oncology targets, while BI will hold global development & commercialization rights, and lead further R&D, manufacturing, & commercialization activities As per…
June 24, 2026

Read more

NEWS

Abbisko Therapeutics Inks ~$1.9B Multi-Target R&D Deal with Eli Lilly

Shots: Abbisko Therapeutics has entered into a strategic research collaboration & license agreement with Eli Lilly to discover & develop novel therapeutics across multiple targets Abbisko will leverage its early-stage drug discovery platform, R&D ecosystem, & development expertise to conduct discovery & early-stage development of novel therapeutics against disease targets selected by Lilly As per…
June 24, 2026

Read more

Load more